New antiviral therapies for hepatitis C

Jacqueline O'Leary, Raymond T. Chung

Research output: Contribution to journalReview articlepeer-review


Hepatitis C affects 170 million people worldwide and is the leading indication for liver transplantation. However, despite this high prevalence and burden of disease, current treatment regimens necessitate long durations of therapy, are often poorly tolerated and have suboptimal rates of sustained virologic response. Therefore, much attention has been directed at the development of new therapeutic agents against specific viral targets. This article reviews modifications of current therapies, outlines the viral life cycle and focuses on novel therapeutic agents currently being studied.

Original languageEnglish (US)
Pages (from-to)235-243
Number of pages9
JournalExpert Review of Anti-Infective Therapy
Issue number2
StatePublished - Apr 2004


  • Hepatits C
  • Interferon
  • New therapies

ASJC Scopus subject areas

  • Microbiology
  • Microbiology (medical)
  • Virology
  • Infectious Diseases


Dive into the research topics of 'New antiviral therapies for hepatitis C'. Together they form a unique fingerprint.

Cite this